Skip to content
CancerIndex

Loading the knowledge graph…

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells — knowledge graph · CancerIndex